Company Of The Day: Johnson & Johnson
What?
Johnson & Johnson (NYSE:JNJ) posted a stronger than expected Q3 2021 profit, with adjusted EPS rising by about 18% year-over-year to about $2.60. While revenues grew 11% to $23.34 billion, they fell short of estimates.
Why?
Relevant Articles
- What’s Next For Johnson & Johnson Stock After Beating Q1 Earnings?
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
The results were driven by a strong performance of the pharmaceuticals business, ongoing recovery in medical devices, and growth in the consumer healthcare space.
So What?
J&J stock rose by about 2% in Tuesday’s trading.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates